PHILADELPHIA, PA – On Friday, Frontage Laboratories, Inc. has agreed to pay $125,000 to resolve allegations that it violated the Controlled Substances Act (CSA) by failing to maintain complete and accurate records of controlled substances and failing to keep one controlled substance secured.
The investigation involved Frontage’s facility in Exton, PA. As part of the settlement, Frontage has entered into a two-year extension of its Memorandum of Agreement (MOA) with the Drug Enforcement Administration (DEA), which includes additional responsibilities regarding handling controlled substances.
U.S. Attorney Jacqueline C. Romero stated, “Companies are responsible for ensuring that all controlled substances are tracked through the distribution chain. Our Office is committed to ensuring total compliance with the Controlled Substances Act, and we will vigorously enforce violations wherever we find them.”
The claims resolved by this settlement are allegations only and there has been no determination of liability.
